Such a reduced sensitivity may arise from a reduced nuclear accumulation of tumor suppressor genes, delayed cell cycle, and/or reduced variation in overall protein expression after CRM1 inhibition, as seen in a fibrosarcoma cell line treated with the SINE KPT-330 [69]. The gene discussed is XPO1; the disease is fibrosarcoma.